Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes

    FRANKLIN, Mass., July 1 /CNW/ -- Echo Therapeutics, Inc. (OTC Bulletin
Board: ECTE) announced today that it has initiated a clinical study of its
Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in
patients with Type 1 and Type 2 diabetes.  The Company expects to complete and
announce the results of the study in the third quarter of 2008. Echo's
non-invasive Symphony tCGM System consists of its Prelude(TM) SkinPrep System,
which incorporates patented and leading-edge skin permeation control
technology, and wireless transmission and proprietary transdermal biosensor
technologies.  Echo's Symphony tCGM System is designed to provide both
diabetes and hospital patients with a reliable, needle-free, easy-to-use,
affordable and comfortable-to-wear continuous glucose monitoring device.
    "Building on the momentum generated from our prior four positive pilot
clinical studies, we are excited to have started our next pilot study in the
important diabetes home use market.  Our new Prelude Skin Prep System is a
competitively unique component of our Symphony tCGM System, enabling our
system to generate painless, needle-free, continuous glucose measurements. The
primary purpose of this new study is to evaluate the performance of our
Symphony tCGM System with Prelude as the new skin permeation element," stated
Patrick T. Mooney, M.D., Echo's Chairman and Chief Executive Officer. "We are
very excited about our significant development progress thus far, and we look
forward to making additional progress with Symphony throughout 2008."
    Echo's pilot clinical study will enroll ten (10) patients with diabetes
(either Type 1 or Type 2) and will compare data obtained from its Symphony
tCGM System with both the "gold standard" YSI Glucose Analyzer and a
widely-used, commercially available "finger-stick" glucometer.  The study will
collect more than 900 data pairs to be used in the analyses.  Reference
glucose measurements will be made at 15 minute intervals for 24 hours with the
study data blinded to study subjects and study personnel.
    About Echo Therapeutics
    Echo Therapeutics is focused on medical devices and specialty
pharmaceuticals. Echo is developing a non-invasive, wireless, transdermal
continuous glucose monitoring (tCGM) system for patients with diabetes and for
use in hospital critical care units, together with a wide range of novel
topical reformulations of widely-used, FDA-approved products.
    Cautionary Statement Regarding Forward Looking Statements
    Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any forward-
looking statements contained herein are based on current expectations, but are
subject to a number of risks and uncertainties. The factors that could cause
actual future results to differ materially from current expectations include,
but are not limited to, risks related to regulatory approvals and the success
of Echo's ongoing studies regarding the efficacy of Echo's Symphony tCGM
System, the failure of future development and preliminary marketing efforts
related to Echo's tCGM systems, risks and uncertainties relating to Echo's
ability to develop, market and sell diagnostic products based on its skin
permeation platform technologies, including the Prelude SkinPrep System, the
availability of substantial additional equity or debt capital to support its
research, development and product commercialization activities, and the
success of its research, development, and regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to its tCGM systems.  Furthermore, Echo's tCGM system has not yet been
approved for sale. The regulatory approval process for its tCGM system
involves, among other factors, successfully completing pilot and pivotal
clinical trials and obtaining a premarket approval, or PMA, from the FDA. The
PMA process requires Echo to prove the safety and efficacy of its tCGM system
to the FDA's satisfaction. This process can be expensive and uncertain, and
there is no guarantee that Echo will be able to submit a PMA for its Symphony
tCGM System or that its Symphony tCGM System will be approved by the FDA in
any specific timeframe or at all. In addition, clinical testing of Echo's
products and eventual commercialization of its products are subject to all of
the risks and uncertainties set forth in its periodic reports filed with the
Securities and Exchange Commission.
    These and other factors are identified and described in more detail in
Echo's filings with the Securities and Exchange Commission, including, without
limitation, its annual report on Form 10-KSB for the year ended December 31,
2007, its quarterly reports on Form 10-Q, and its current reports on Form 8-K.
The foregoing list of factors is not exhaustive. Echo Therapeutics, Inc.
undertakes no obligation to publicly update or revise any forward-looking

    For More Information:
    Patrick T. Mooney, M.D.                  Lilian Stern
    Chairman and Chief Executive Officer     Stern Investor Relations
    (856) 429-8778                           (212) 362-1200

For further information:

For further information: Patrick T. Mooney, M.D., Chairman and Chief 
Executive Officer, +1-856-429-8778, or Lilian Stern, Stern Investor Relations,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890